February 16, 2021
10 min watch
Save
VIDEO: Fatty Liver Foundation looks to ‘blunt’ liver disease epidemic
Issue: April 2021
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Healio Gastroenterology spoke with Wayne Eskridge, founder and CEO of the Fatty Liver Foundation on the goals the foundation has this year, including increasing screening for liver disease and working around the COVID-19 pandemic.
He said nonalcoholic steatohepatitis is more hazardous than diabetes and smoking, and it is not spoken of enough. He said more people need to be made aware of NASH. Eskridge said the foundation’s goal is to screen 1 million people for liver disease over the next few years and to “blunt the epidemic” of liver disease.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Wayne Eskridge and the Fatty Liver Foundation report receiving program support and educational grants from Allergan, Amazon, Bristol-Myers Squibb, Celgene, Clinical Care Options, Continuum Clinical, Echosens, Eskridge Family Trust, Fibronostics, First Line Creative, Gilead Sciences, Global Engage, Google, Health Business Solutions, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Meetrix, Merck & Co., Inc. NetNoggin, Prosciento, Pfizer, Terns Pharmaceuticals and various private and philanthropic individual donors.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.